Synlogic, Inc. (SYBX): Total Assets
$15.45M
As of 2025-12-31
$13.48M
As of 2026-06-30
-48.2%
3-year compound annual growth
-36.0%
5-year compound annual growth
-16.2%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.45M | -22.1% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $19.83M | -73.8% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $75.55M | -31.9% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $110.86M | -36.6% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $174.74M | +21.5% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $143.84M | -23.7% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $188.57M | +34.4% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $140.34M | +40.8% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $99.70M | +397.5% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $20.04M | -78.0% | 2018-03-20, Balance as of period end |
| 2015-12-31 | $90.92M | +825.4% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $9.82M | n/a | 2016-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Synlogic, Inc. (SYBX) | 2025-12-31 | $15.45M | -22.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare SYBX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗